851044-96-7

Upstream product

• 1127-74-8 1,2,3,4-tetrahydro-5H-benzo[b] azepin-5-one 
• 98-59-9 p-toluenesulfonyl chloride 
• 24310-36-9 1-tosyl-2,3,4,5-tetrahydro-1H-1-benzazepin-5-one 
• 616-38-6 carbonic acid dimethyl ester 
• 100627-39-2 N-(3-ethoxycarbonyl-propyl)-N-(toluene-4-sulfonyl)-anthranilic acid methyl ester 

Downstream Products

• 54621-07-7 4-methyl-5-oxo-1-tosyl-2,3,4,5-tetrahydro-1H-benzo[b]azepine-4-carboxylic acid methyl ester 
• 24310-36-9 1-tosyl-2,3,4,5-tetrahydro-1H-1-benzazepin-5-one 

Relevant academic research and scientific papers

NOVEL BENZO [...] DERIVATIVES AND THEIR MEDICAL USE

One objective of the present invention is to provide a compound having V2 receptor agonist effect. The pharmaceutical composition of this invention uses a compound expressed by the following general formula (I) or its pharmacologically acceptable salt as an active ingredient, wherein, R1 represents the following formula: wherein, A represents a lower alkylene group or the like which may be substituted with a lower alkyl group; R6 represents a hydrogen atom or the like; R7 represents a hydroxyl group, an aromatic heterocyclic group which may be substituted with a lower alkyl group, amine methyl acyl or the like; R2 represents a hydrogen atom or a lower alkyl group; R3 represents a lower alkyl group which may be substituted with 1 to 3 fluorine atoms or a halogen atom; R4 represents 5-membered aromatic monocyclic heterocyclic group, or 5-membered non-aromatic monocyclic heterocyclic group or the like, wherein the heterocyclic group contains at least one nitrogen atom, and may be substituted with a lower alkyl group; R 5 represents a lower alkyl group or a halogen atom or the like.

NOVEL BENZOAZEPINE DERIVATIVE AND MEDICAL USE THEREOF

A compound having a V2 receptor agonistic activity is provided. Providing a pharmaceutical composition which contains, as an active ingredient, a compound represented by general formula (I) described below: [R1 is formula described below: (A is a lower alkylene group which may be substituted with lower alkyl group; R6 is a hydrogen atom; R7 is a hydroxyl group, an aromatic heterocyclic group which may be substituted with lower alkyl group, carbamoyl group); R2 is a hydrogen atom or lower alkyl group; R3 is lower alkyl group which may be substituted with 1-3 fluorine atoms, or halogen atom; R4 is a five-membered aromatic monocyclic heterocyclic group, five-membered non-aromatic monocyclic heterocyclic group, (provided each heterocyclic groups contain at least one nitrogen atom and may be substituted with a lower alkyl group); and R5 is a lower alkyl group, halogen atom], or pharmacologically acceptable salt thereof.

COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA

Compounds of formula I wherein n, m, p, q, Y, R1 R2, R3, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating artherosclerosis and its sequelae.